Clinical TrialJul 17, 2026, 06:07 AM
Adlai Nortye Doses First Patient in Weekly AN9025 Phase 1 Arm
AI Summary
Adlai Nortye Ltd. announced that the first patient has been dosed in the intermittent weekly dosing (QW) arm of its global Phase 1 clinical trial for AN9025, a pan-RAS(ON) inhibitor. This milestone advances the company's strategy to evaluate AN9025 with a differentiated approach, as preclinical data suggests weekly dosing could widen the therapeutic window and improve tolerability. Both the daily (QD) and weekly (QW) dose escalation arms are now actively enrolling patients, with initial data from the QD arm anticipated in the first half of 2027.
Key Highlights
- First patient dosed in the intermittent weekly dosing (QW) arm of the global Phase 1 trial for AN9025.
- AN9025 is a pan-RAS(ON) inhibitor being developed for advanced or metastatic solid tumors with RAS mutations.
- Intermittent weekly dosing aims to widen the therapeutic window, improve tolerability, and combinability.
- Both daily (QD) and weekly (QW) dose escalation arms are currently enrolling patients.
- Initial Phase 1 dose escalation data from the QD arm is expected in the first half of 2027.
- The trial is a collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm).
Price Impact
More from ANL